Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Zydus Lifesciences Limited has 5 pending office actions in Biotechnology & Pharmaceuticals. Each matter is assigned to a different examiner and a different art unit, so the docket is fully distributed across its examination paths.
OH, TAYLOR V is the busiest examiner, with 1 pending matter. Counsel should use matter-specific preparation and direct tracking rather than relying on a repeated examiner strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OH, TAYLOR V | 1 | 81.3% | +15.3% |
| JANOSKO, CHASITY PAIGE | 1 | 15.9% | +63.6% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 51.8% | +27.5% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688677 | DESIDUSTAT PARTICLES AND COMPOSITIONS THEREOF | JANOSKO, CHASITY PAIGE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293826 | STABLE PHARMACEUTICAL COMPOSITIONS OF APOMORPHINE | ATKINSON, JOSHUA ALEXANDER | 73d overdue |
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | — |
| 18688677 | DESIDUSTAT PARTICLES AND COMPOSITIONS THEREOF | JANOSKO, CHASITY PAIGE | — |
| 18325249 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF COPPER HISTIDINATE | KWON, JOHN SEUNGJAI | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1613 | 1 |
| 1612 | 1 |
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19434846 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY | OH, TAYLOR V | 1625 | §103 | Final Rejection | — | Pending | Dec 29, 2025 |
| 18688677 | DESIDUSTAT PARTICLES AND COMPOSITIONS THEREOF | JANOSKO, CHASITY PAIGE | 1613 | §103 | Final Rejection | — | Pending | Mar 01, 2024 |
| 18293826 | STABLE PHARMACEUTICAL COMPOSITIONS OF APOMORPHINE | ATKINSON, JOSHUA ALEXANDER | 1612 | §103 | Final Rejection | 73d overdue | Pending | Jan 31, 2024 |
| 18578843 | PHARMACEUTICAL COMPOSITIONS OF OZANIMOD | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Final Rejection | 30d overdue | Pending | Jan 12, 2024 |
| 18325249 | LYOPHILIZED PHARMACEUTICAL COMPOSITIONS OF COPPER HISTIDINATE | KWON, JOHN SEUNGJAI | 1615 | §103 | Non-Final OA | — | Pending | May 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZydus Lifesciences Limited has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Taylor V Oh has the most, with 1 of Zydus Lifesciences Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
